The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Trimelamol     [[4,6-bis(hydroxymethyl- methyl-amino)-1,3...

Synonyms: Trimethyl TMM, CHEMBL133987, NCIMech_000583, SureCN1419460, CCG-35699, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NSC 283162


High impact information on NSC 283162

  • Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine) [5].
  • Trimelamol gave rise to DNA-interstrand crosslinks in naked plasmid DNA and in cultured cell lines, whereas the analogues failed to do so under a variety of experimental conditions [6].
  • Stable analogues of the antitumour agent trimelamol retain in vitro cytotoxicity in drug-sensitive and resistant rodent and human cell lines [7].
  • An investigation of the mechanism of action of the antitumour agent trimelamol has established that it is an efficient interstrand DNA cross-linker in vitro, comparable to nitrogen mustards such as melphalan [8].
  • This difference did not correlate with plasma protein binding which is greater for PMM (68.2%) than for Trimelamol (17.5%) [3].

Chemical compound and disease context of NSC 283162


Biological context of NSC 283162

  • Finally, t1/2 values have been determined for trimelamol in aqueous solution at different temperatures, and the kinetics of formation of degradation products has been studied over a period of 30 h under a variety of conditions of pH and temperature [10].

Associations of NSC 283162 with other chemical compounds


Gene context of NSC 283162

  • In vivo studies using a human ovarian cancer xenograft model PXN/65 showed TM to be curative in the dose range of 15-60 mg/kg i.p. daily x 5, for 4 weeks [11].

Analytical, diagnostic and therapeutic context of NSC 283162

  • An HPLC method was used to obtain kinetic data for the loss of trimelamol and to monitor the order of appearance of three degradation products [10].
  • The prototype containing 30 mg/mL trimelamol in a 50% PEG 3400-aqueous vehicle was found to be the optimal formulation for sterile filtration, lyophilization, and subsequent reconstitution [12].


  1. Phase II trial of trimelamol in refractory ovarian cancer. Judson, I.R., Calvert, A.H., Gore, M.E., Balmanno, K., Gumbrell, L.A., Perren, T., Wiltshaw, E. Br. J. Cancer (1991) [Pubmed]
  2. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Bermudez, J., Boyle, E.A., Miner, W.D., Sanger, G.J. Br. J. Cancer (1988) [Pubmed]
  3. Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity. Judson, I.R., Rutty, C.J., Abel, G., Graham, M.A. Br. J. Cancer (1986) [Pubmed]
  4. Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation. Rutty, C.J., Judson, I.R., Abel, G., Goddard, P.M., Newell, D.R., Harrap, K.R. Cancer Chemother. Pharmacol. (1986) [Pubmed]
  5. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine). Judson, I.R., Calvert, A.H., Rutty, C.J., Abel, G., Gumbrell, L.A., Graham, M.A., Evans, B.D., Wilman, D.E., Ashley, S.E., Cairnduff, F. Cancer Res. (1989) [Pubmed]
  6. The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studies. Coley, H.M., Brooks, N., Phillips, D.H., Hewer, A., Jenkins, T.C., Jarman, M., Judson, I.R. Biochem. Pharmacol. (1995) [Pubmed]
  7. Stable analogues of the antitumour agent trimelamol retain in vitro cytotoxicity in drug-sensitive and resistant rodent and human cell lines. Coley, H.M., Jarman, M., Brooks, N., Thornton, T.J., Judson, I.R. Eur. J. Cancer (1994) [Pubmed]
  8. N2,N4,N6-tri(hydroxymethyl)-N2,N4,N6-trimethylmelamine (trimelamol) is an efficient DNA cross-linking agent in vitro. Jackson, C., Hartley, J.A., Jenkins, T.C., Godfrey, R., Saunders, R., Thurston, D.E. Biochem. Pharmacol. (1991) [Pubmed]
  9. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts. Boven, E., Nauta, M.M., Schlüper, H.M., Erkelens, C.A., Pinedo, H.M. Cancer Chemother. Pharmacol. (1986) [Pubmed]
  10. Studies on the stability of trimelamol, a carbinolamine-containing antitumor drug. Jackson, C., Crabb, T.A., Gibson, M., Godfrey, R., Saunders, R., Thurston, D.E. Journal of pharmaceutical sciences. (1991) [Pubmed]
  11. The activity of N-(hydroxymethyl) melamines in fresh human ovarian tumour cells and xenografts. Coley, H.M., Jarman, M., Jones, M., Sargent, J.M., Kubota, T., Lee, N.C., Goddard, P.M., Elgie, A.W., Williamson, C., Taylor, C.G., Judson, I.R. Anticancer Res. (1996) [Pubmed]
  12. Development of a parenteral formulation of trimelamol, a synthetic S-triazine carbinolamine-containing cytotoxic agent. Gibson, M., Denham, A.J., Taylor, P.M., Payne, N.I. Journal of parenteral science and technology : a publication of the Parenteral Drug Association. (1990) [Pubmed]
WikiGenes - Universities